Alkermes PLC Company Profile (NASDAQ:ALKS)

About Alkermes PLC

Alkermes PLC logoAlkermes Public Limited Company is a biopharmaceutical company. The Company is engaged in researching, developing and commercializing, both with partners and on its own, pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of approximately 20 products and a clinical pipeline of product candidates that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis. Its products include ARISTADA, VIVITROL, RISPERDAL CONSTA, INVEGA SUSTENNA/XEPLION & INVEGA TRINZA, AMPYRA/FAMPYRA, BYDUREON, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, Aripiprazole Lauroxil Two-Month Dose, ALKS 7119 and RDB 1450. Its product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release technology.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Delivery
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: ALKS
  • CUSIP: G0176710
Key Metrics:
  • Previous Close: $55.55
  • 50 Day Moving Average: $55.79
  • 200 Day Moving Average: $52.05
  • 52-Week Range: $27.14 - $60.74
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 75.79
  • P/E Growth: -14.78
  • Market Cap: $8.32B
  • Outstanding Shares: 152,430,000
  • Beta: 2.12
  • Net Margins: -36.92%
  • Return on Equity: -12.75%
  • Return on Assets: -8.98%
  • Debt-to-Equity Ratio: 0.23%
  • Current Ratio: 4.24%
  • Quick Ratio: 3.96%
Additional Links:
Companies Related to Alkermes PLC:

Analyst Ratings

Consensus Ratings for Alkermes PLC (NASDAQ:ALKS) (?)
Ratings Breakdown: 3 Hold Ratings, 7 Buy Ratings
Consensus Rating:Buy (Score: 2.70)
Consensus Price Target: $61.27 (12.28% upside)

Analysts' Ratings History for Alkermes PLC (NASDAQ:ALKS)
DateFirmActionRatingPrice TargetDetails
2/16/2017Cantor FitzgeraldReiterated RatingNeutral$51.00View Rating Details
11/17/2016Jefferies Group LLCReiterated RatingBuy$70.00View Rating Details
11/2/2016Cowen and CompanyReiterated RatingBuyView Rating Details
10/21/2016Morgan StanleyUpgradeUnderweight -> Hold$62.00View Rating Details
10/21/2016Leerink SwannBoost Price TargetOutperform$57.00 -> $70.00View Rating Details
10/21/2016Credit Suisse GroupBoost Price TargetOutperform$52.00 -> $70.00View Rating Details
10/21/2016J P Morgan Chase & CoUpgradeNeutral -> Overweight$51.00 -> $78.00View Rating Details
9/27/2016Citigroup Inc.Boost Price TargetNeutral$44.00 -> $53.00View Rating Details
7/29/2016Barclays PLCBoost Price TargetOverweight$65.00 -> $66.00View Rating Details
5/26/2016Evercore ISIInitiated CoverageBuy$59.00View Rating Details
2/22/2016Goldman Sachs Group, Inc. (The)Lower Price Target$57.00 -> $35.00View Rating Details
1/21/2016GuggenheimReiterated RatingHoldView Rating Details
2/25/2015Bank of America CorpSet Price TargetSell$45.00View Rating Details
(Data available from 2/21/2015 forward)


Earnings History for Alkermes PLC (NASDAQ:ALKS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/15/2017Q416$0.04$0.15$206.38 million$213.50 millionViewListenView Earnings Details
11/2/2016Q316($0.06)($0.09)$186.39 million$180.20 millionViewListenView Earnings Details
7/28/2016Q216($0.10)($0.01)$174.15 million$195.20 millionViewListenView Earnings Details
4/28/2016Q116($0.20)($0.16)$153.64 million$156.80 millionViewListenView Earnings Details
2/25/2016Q415($0.18)($0.15)$161.24 million$163.10 millionViewListenView Earnings Details
10/29/2015Q315($0.21)($0.18)$151.77 million$152.70 millionViewListenView Earnings Details
7/30/2015Q215($0.10)($0.09)$142.80 million$151.40 millionViewListenView Earnings Details
4/30/2015Q115($0.03)$0.06$146.60 million$161.20 millionViewListenView Earnings Details
2/24/2015Q414$0.04$0.11$161.70 million$175.20 millionViewListenView Earnings Details
10/29/2014Q314$0.02$0.03$155.53 million$160.00 millionViewListenView Earnings Details
7/31/2014Q314$0.14$0.11$146.91 million$153.40 millionViewListenView Earnings Details
4/30/2014Q1$0.10$0.11$135.79 million$130.21 millionViewListenView Earnings Details
2/27/2014Q114$0.20$0.27$142.93 million$154.50 millionViewListenView Earnings Details
10/31/2013$0.22$0.22$137.35 million$139.80 millionViewListenView Earnings Details
7/25/2013Q1 2014$0.22$0.30$131.50 million$138.60 millionViewListenView Earnings Details
5/23/2013Q4 2013$0.17$0.40$128.01 million$163.40 millionViewListenView Earnings Details
1/31/2013Q3 2013$0.23$0.34$130.81 million$135.90 millionViewListenView Earnings Details
11/1/2012Q213$0.11$0.17$121.62 million$124.00 millionViewN/AView Earnings Details
7/26/2012$0.16$0.39ViewN/AView Earnings Details
5/17/2012($0.16)($0.14)ViewN/AView Earnings Details
2/2/2012($0.21)($0.11)ViewN/AView Earnings Details
11/3/2011($0.10)($0.22)ViewN/AView Earnings Details
8/1/2011($0.11)$0.02ViewN/AView Earnings Details
5/18/2011($0.14)($0.14)ViewN/AView Earnings Details
2/3/2011($0.15)($0.06)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Alkermes PLC (NASDAQ:ALKS)
Current Year EPS Consensus Estimate: $0.13 EPS
Next Year EPS Consensus Estimate: $0.72 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($0.16)($0.16)($0.16)
Q3 20162($0.33)($0.17)($0.25)
Q4 20161($0.14)($0.14)($0.14)
Q2 20171($0.16)($0.16)($0.16)
Q3 20171($0.15)($0.15)($0.15)
Q4 20171($0.10)($0.10)($0.10)
(Data provided by Zacks Investment Research)


Dividend History for Alkermes PLC (NASDAQ:ALKS)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Alkermes PLC (NASDAQ:ALKS)
Insider Ownership Percentage: 4.75%
Institutional Ownership Percentage: 95.52%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/16/2017Elliot EhrichCMOSell11,000$56.68$623,480.00View SEC Filing  
2/1/2017Paul J MitchellDirectorSell1,500$54.45$81,675.00View SEC Filing  
1/17/2017Elliot EhrichCMOSell11,983$54.32$650,916.56View SEC Filing  
1/9/2017Mark StejbachSVPSell547$60.27$32,967.69View SEC Filing  
1/9/2017Shane CookeInsiderSell550$60.27$33,148.50View SEC Filing  
1/6/2017Elliot EhrichCMOSell10,000$59.44$594,400.00View SEC Filing  
1/6/2017Mark StejbachSVPSell9,453$60.05$567,652.65View SEC Filing  
1/6/2017Shane CookeInsiderSell9,450$60.06$567,567.00View SEC Filing  
1/4/2017Robert A BreyerDirectorSell4,000$60.00$240,000.00View SEC Filing  
1/3/2017David Joseph GaffinSVPSell2,500$55.40$138,500.00View SEC Filing  
1/3/2017Paul J MitchellDirectorSell1,500$55.40$83,100.00View SEC Filing  
12/16/2016Gordon G PughCOOSell21,458$57.65$1,237,053.70View SEC Filing  
12/15/2016Elliot EhrichCMOSell5,000$55.99$279,950.00View SEC Filing  
12/14/2016James M FratesSVPSell25,000$54.73$1,368,250.00View SEC Filing  
12/12/2016Elliot EhrichCMOSell16,983$55.15$936,612.45View SEC Filing  
12/8/2016Kathryn L BibersteinCAOSell14,145$56.13$793,958.85View SEC Filing  
12/7/2016James M. FratesSVPSell23,731$56.28$1,335,580.68View SEC Filing  
12/1/2016Kathryn L BibersteinCAOSell15,000$56.13$841,950.00View SEC Filing  
11/30/2016Michael J LandineSVPSell10,000$57.51$575,100.00View SEC Filing  
11/29/2016Richard F PopsDirectorSell30,000$56.98$1,709,400.00View SEC Filing  
11/22/2016Richard F PopsDirectorSell30,000$58.66$1,759,800.00View SEC Filing  
10/4/2016Paul J MitchellDirectorSell2,000$47.42$94,840.00View SEC Filing  
9/22/2016Elliot EhrichCMOSell5,000$50.83$254,150.00View SEC Filing  
9/16/2016Elliot EhrichCMOSell5,000$48.87$244,350.00View SEC Filing  
9/6/2016David Joseph GaffinSVPSell2,382$45.92$109,381.44View SEC Filing  
9/6/2016Elliot EhrichCMOSell10,000$46.02$460,200.00View SEC Filing  
9/6/2016Iain Michael BrownCAOSell29,976$45.92$1,376,497.92View SEC Filing  
9/6/2016Paul J MitchellDirectorSell2,000$45.92$91,840.00View SEC Filing  
8/4/2016Paul J MitchellDirectorSell2,000$49.48$98,960.00View SEC Filing  
7/27/2016Elliot EhrichCMOSell35,199$51.95$1,828,588.05View SEC Filing  
7/5/2016Paul J MitchellDirectorSell2,000$45.81$91,620.00View SEC Filing  
6/6/2016Paul J MitchellDirectorSell2,000$44.98$89,960.00View SEC Filing  
5/4/2016Paul J MitchellDirectorSell2,000$38.60$77,200.00View SEC Filing  
4/20/2016Michael J LandineSVPSell16,875$41.09$693,393.75View SEC Filing  
4/19/2016Richard F PopsCEOSell18,750$40.15$752,812.50View SEC Filing  
4/18/2016Iain Michael BrownCAOSell5,368$39.27$210,801.36View SEC Filing  
4/13/2016Elliot EhrichCMOSell11,698$37.66$440,546.68View SEC Filing  
4/12/2016Richard F PopsCEOSell25,000$37.79$944,750.00View SEC Filing  
4/4/2016Paul J MitchellDirectorSell2,000$35.65$71,300.00View SEC Filing  
3/22/2016Richard F PopsCEOSell25,000$31.77$794,250.00View SEC Filing  
3/15/2016Richard F PopsCEOSell25,000$31.40$785,000.00View SEC Filing  
3/4/2016Paul J MitchellDirectorSell2,000$32.80$65,600.00View SEC Filing  
3/3/2016David W AnsticeDirectorBuy5,000$32.87$164,350.00View SEC Filing  
2/4/2016Paul J. MitchellDirectorSell2,000$32.81$65,620.00View SEC Filing  
1/4/2016Robert A BreyerDirectorSell2,000$77.33$154,660.00View SEC Filing  
12/28/2015Mark StejbachinsiderSell10,000$80.24$802,400.00View SEC Filing  
12/23/2015Shane CookeinsiderSell18,000$77.23$1,390,140.00View SEC Filing  
12/7/2015Michael J. LandineSVPSell3,750$73.02$273,825.00View SEC Filing  
12/7/2015Richard F. PopsCEOSell37,500$72.06$2,702,250.00View SEC Filing  
12/1/2015Mark StejbachinsiderSell18,000$72.18$1,299,240.00View SEC Filing  
12/1/2015Michael J. LandineSVPSell10,000$72.18$721,800.00View SEC Filing  
12/1/2015Richard F. PopsCEOSell50,000$72.29$3,614,500.00View SEC Filing  
12/1/2015Robert A BreyerDirectorSell2,000$73.46$146,920.00View SEC Filing  
11/23/2015Shane CookeinsiderSell18,000$72.62$1,307,160.00View SEC Filing  
11/2/2015Mark StejbachinsiderSell18,000$72.06$1,297,080.00View SEC Filing  
11/2/2015Robert A BreyerDirectorSell2,000$71.80$143,600.00View SEC Filing  
10/29/2015Iain Michael BrownCAOSell10,822$69.99$757,431.78View SEC Filing  
10/23/2015Shane CookeinsiderSell18,000$62.03$1,116,540.00View SEC Filing  
10/13/2015James M. FratesCFOSell20,000$59.78$1,195,600.00View SEC Filing  
10/2/2015Robert A. BreyerDirectorSell2,000$60.00$120,000.00View SEC Filing  
9/23/2015Shane CookeinsiderSell18,000$67.09$1,207,620.00View SEC Filing  
9/17/2015Michael J. LandineSVPSell10,000$71.20$712,000.00View SEC Filing  
9/17/2015Richard F. PopsCEOSell50,000$71.27$3,563,500.00View SEC Filing  
9/15/2015James M. FratesCFOSell20,000$71.10$1,422,000.00View SEC Filing  
9/10/2015Michael J. LandineSVPSell10,000$67.61$676,100.00View SEC Filing  
9/10/2015Richard F. PopsCEOSell50,000$67.57$3,378,500.00View SEC Filing  
9/1/2015Robert A BreyerDirectorSell2,000$61.43$122,860.00View SEC Filing  
8/24/2015Shane CookeinsiderSell18,000$57.65$1,037,700.00View SEC Filing  
7/23/2015Shane CookeInsiderSell18,000$69.79$1,256,220.00View SEC Filing  
7/20/2015Gordon G PughCOOSell18,750$70.10$1,314,375.00View SEC Filing  
7/14/2015James M FratesCFOSell20,000$65.79$1,315,800.00View SEC Filing  
7/1/2015Gordon G PughCOOSell13,750$65.13$895,537.50View SEC Filing  
7/1/2015Robert A BreyerDirectorSell2,000$64.90$129,800.00View SEC Filing  
6/23/2015Shane CookeInsiderSell18,000$66.84$1,203,120.00View SEC Filing  
6/17/2015Paul J MitchellDirectorSell15,500$65.10$1,009,050.00View SEC Filing  
6/16/2015Gordon G PughCOOSell32,977$63.11$2,081,178.47View SEC Filing  
6/16/2015James M FratesCFOSell10,000$58.63$586,300.00View SEC Filing  
6/1/2015Paul J MitchellDirectorSell1,500$60.78$91,170.00View SEC Filing  
6/1/2015Rebecca PetersonSVPSell21,983$60.05$1,320,079.15View SEC Filing  
5/26/2015Rebecca PetersonSVPSell1,322$60.49$79,967.78View SEC Filing  
5/26/2015Shane CookeInsiderSell18,000$60.31$1,085,580.00View SEC Filing  
5/22/2015Rebecca PetersonSVPSell28,558$61.71$1,762,314.18View SEC Filing  
5/12/2015James M FratesCFOSell10,000$59.34$593,400.00View SEC Filing  
5/4/2015Robert A BreyerDirectorSell2,000$60.00$120,000.00View SEC Filing  
5/1/2015Paul J MitchellDirectorSell1,500$55.79$83,685.00View SEC Filing  
4/23/2015Shane CookeInsiderSell18,000$62.55$1,125,900.00View SEC Filing  
4/21/2015Elliot EhrichCMOSell25,000$62.39$1,559,750.00View SEC Filing  
4/15/2015Gordon G PughCOOSell13,750$63.21$869,137.50View SEC Filing  
4/15/2015James M FratesCFOSell10,000$62.42$624,200.00View SEC Filing  
4/15/2015Paul J MitchellDirectorSell1,500$62.71$94,065.00View SEC Filing  
4/1/2015Robert A BreyerDirectorSell5,000$61.22$306,100.00View SEC Filing  
3/23/2015Shane CookeInsiderSell18,000$65.33$1,175,940.00View SEC Filing  
3/16/2015Elliot EhrichCMOSell18,000$66.81$1,202,580.00View SEC Filing  
3/10/2015James M FratesCFOSell10,000$66.25$662,500.00View SEC Filing  
3/5/2015Rebecca PetersonSVPSell17,737$71.37$1,265,889.69View SEC Filing  
3/2/2015Gordon G PughCOOSell15,000$71.39$1,070,850.00View SEC Filing  
3/2/2015Robert A BreyerDirectorSell5,000$70.86$354,300.00View SEC Filing  
2/23/2015Shane CookeInsiderSell18,000$74.29$1,337,220.00View SEC Filing  
2/17/2015Elliot EhrichCMOSell18,000$70.87$1,275,660.00View SEC Filing  
2/3/2015James M FratesCFOSell10,000$70.83$708,300.00View SEC Filing  
2/2/2015Gordon G PughCOOSell15,000$72.01$1,080,150.00View SEC Filing  
2/2/2015Robert A BreyerDirectorSell5,000$72.91$364,550.00View SEC Filing  
1/26/2015Gordon G PughCOOSell15,000$70.02$1,050,300.00View SEC Filing  
1/23/2015Shane CookeInsiderSell118,000$69.13$8,157,340.00View SEC Filing  
1/16/2015Floyd E BloomDirectorSell20,000$67.12$1,342,400.00View SEC Filing  
1/15/2015Elliot EhrichCMOSell18,375$66.45$1,221,018.75View SEC Filing  
1/15/2015James M FratesCFOSell10,000$66.86$668,600.00View SEC Filing  
1/7/2015Kathryn L BibersteinSVPSell28,374$65.00$1,844,310.00View SEC Filing  
1/2/2015Robert A BreyerDirectorSell5,000$58.57$292,850.00View SEC Filing  
12/11/2014Richard F PopsCEOSell100,000$56.04$5,604,000.00View SEC Filing  
12/10/2014James M FratesCFOSell18,870$56.07$1,058,040.90View SEC Filing  
12/9/2014Michael J LandineSVPSell18,000$56.82$1,022,760.00View SEC Filing  
12/5/2014Kathryn L BibersteinSVPSell15,433$57.61$889,095.13View SEC Filing  
12/1/2014Robert A BreyerDirectorSell5,000$54.64$273,200.00View SEC Filing  
11/19/2014James M FratesCFOSell8,000$53.86$430,880.00View SEC Filing  
11/13/2014Richard F PopsCEOSell100,000$52.87$5,287,000.00View SEC Filing  
11/7/2014James M FratesCFOSell13,303$49.98$664,883.94View SEC Filing  
11/6/2014Kathryn L BibersteinSVPSell20,000$50.54$1,010,800.00View SEC Filing  
11/3/2014Robert A BreyerDirectorSell5,000$50.05$250,250.00View SEC Filing  
10/23/2014Gordon G PughCOOSell14,577$45.00$655,965.00View SEC Filing  
10/8/2014James M FratesCFOSell16,000$41.00$656,000.00View SEC Filing  
10/1/2014Robert A BreyerDirectorSell5,000$42.59$212,950.00View SEC Filing  
9/24/2014James M FratesCFOSell16,000$45.29$724,640.00View SEC Filing  
9/18/2014Michael J LandineSVPSell15,000$45.60$684,000.00View SEC Filing  
9/17/2014Gordon G PughCOOSell14,900$45.04$671,096.00View SEC Filing  
9/17/2014Richard F PopsCEOSell50,000$44.89$2,244,500.00View SEC Filing  
9/10/2014James M FratesCFOSell16,000$43.18$690,880.00View SEC Filing  
9/2/2014Gordon G PughCOOSell1,100$45.08$49,588.00View SEC Filing  
9/2/2014Robert A BreyerDirectorSell5,000$45.12$225,600.00View SEC Filing  
8/27/2014James M FratesCFOSell16,000$45.08$721,280.00View SEC Filing  
8/26/2014Gordon G PughCOOSell16,000$45.00$720,000.00View SEC Filing  
8/13/2014James M FratesCFOSell15,000$41.37$620,550.00View SEC Filing  
8/11/2014Elliot EhrichCMOSell16,667$41.65$694,180.55View SEC Filing  
8/4/2014Gordon G PughCOOSell23,250$43.20$1,004,400.00View SEC Filing  
8/1/2014Robert A BreyerDirectorSell5,000$42.53$212,650.00View SEC Filing  
7/16/2014James M FratesCFOSell8,000$46.50$372,000.00View SEC Filing  
7/9/2014Elliot EhrichCMOSell16,667$47.41$790,182.47View SEC Filing  
7/9/2014James M FratesCFOSell7,000$47.41$331,870.00View SEC Filing  
7/3/2014Michael J LandineSVPSell7,000$51.31$359,170.00View SEC Filing  
7/2/2014Richard F PopsCEOSell50,000$51.69$2,584,500.00View SEC Filing  
7/1/2014Gordon G PughCOOSell16,000$46.49$743,840.00View SEC Filing  
7/1/2014Robert A BreyerDirectorSell5,000$50.57$252,850.00View SEC Filing  
6/26/2014Michael J LandineSVPSell10,000$49.92$499,200.00View SEC Filing  
6/25/2014James M FratesCFOSell7,000$50.22$351,540.00View SEC Filing  
6/25/2014Richard F PopsCEOSell50,000$49.87$2,493,500.00View SEC Filing  
6/20/2014Paul J MitchellDirectorSell17,000$50.00$850,000.00View SEC Filing  
6/19/2014Elliot EhrichCMOSell17,282$47.10$813,982.20View SEC Filing  
6/19/2014Michael J LandineSVPSell10,000$47.01$470,100.00View SEC Filing  
6/18/2014Richard F PopsCEOSell50,000$46.72$2,336,000.00View SEC Filing  
6/17/2014Kathryn L BibersteinSVPSell8,400$47.41$398,244.00View SEC Filing  
6/11/2014James M FratesCFOSell7,000$47.72$334,040.00View SEC Filing  
6/9/2014Elliot EhrichCMOSell16,667$48.15$802,516.05View SEC Filing  
6/2/2014Gordon G PughCOOSell16,000$45.34$725,440.00View SEC Filing  
6/2/2014Robert A BreyerDirectorSell5,000$45.18$225,900.00View SEC Filing  
5/30/2014Rebecca PetersonSVPSell21,981$45.86$1,008,048.66View SEC Filing  
5/23/2014Rebecca PetersonSVPSell1,321$45.08$59,550.68View SEC Filing  
5/22/2014Elliot EhrichCMOSell2,378$44.49$105,797.22View SEC Filing  
5/22/2014Gordon PughCOOSell15,700$45.25$710,425.00View SEC Filing  
5/22/2014Rebecca PetersonSVPSell19,807$44.02$871,904.14View SEC Filing  
5/21/2014Elliot EhrichCMOSell1,981$44.00$87,164.00View SEC Filing  
5/21/2014James FratesCFOSell7,000$44.30$310,100.00View SEC Filing  
5/20/2014Rebecca PetersonSVPSell20,307$44.05$894,523.35View SEC Filing  
5/19/2014Elliot EhrichCMOSell2,206$43.55$96,071.30View SEC Filing  
5/8/2014Floyd BloomDirectorSell10,000$46.16$461,600.00View SEC Filing  
5/5/2014Robert BreyerDirectorSell5,000$46.72$233,600.00View SEC Filing  
5/1/2014Paul MitchellDirectorSell1,000$45.90$45,900.00View SEC Filing  
4/9/2014James FratesCFOSell7,000$42.91$300,370.00View SEC Filing  
4/1/2014Paul MitchellDirectorSell1,500$44.14$66,210.00View SEC Filing  
3/19/2014James FratesCFOSell7,000$46.84$327,880.00View SEC Filing  
3/11/2014Wendy DixonDirectorBuy1,600$47.37$75,792.00View SEC Filing  
3/5/2014James FratesCFOSell7,000$47.78$334,460.00View SEC Filing  
2/18/2014Elliot EhrichCMOSell7,718$52.45$404,809.10View SEC Filing  
2/3/2014Paul MitchellDirectorSell1,500$48.15$72,225.00View SEC Filing  
1/21/2014Elliot EhrichCMOSell7,718$48.61$375,171.98View SEC Filing  
1/16/2014Elliot EhrichCMOSell14,555$47.35$689,179.25View SEC Filing  
1/16/2014Gordon PughCOOSell30,000$47.16$1,414,800.00View SEC Filing  
1/16/2014James FratesCFOSell7,000$47.40$331,800.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Alkermes PLC (NASDAQ:ALKS)
DateHeadline logoALKERMES PLC. Files SEC form 10-K, Annual Report (NASDAQ:ALKS) - February 17 at 6:38 PM logoAlkermes Plc :ALKS-US: Earnings Analysis: 2016 By the Numbers : February 17, 2017 (NASDAQ:ALKS) - February 17 at 6:38 PM logoEARNINGS SUMMARY: Details of Alkermes plc Q4 Earnings Report (NASDAQ:ALKS) - February 16 at 8:33 PM logoAlkermes plc (ALKS) Tops Q4 EPS by 11c (NASDAQ:ALKS) - February 16 at 8:33 PM logoAlkermes plc (ALKS) Tops Q4 EPS by 11c (NASDAQ:ALKS) - February 16 at 8:33 PM logoAlkermes plc (ALKS) Tops Q4 EPS by 11c (NASDAQ:ALKS) - February 16 at 8:33 PM logoQ4 2016 Alkermes Plc Earnings Release - Before Market Open (NASDAQ:ALKS) - February 16 at 8:33 PM logoQ4 2016 Alkermes Plc Earnings Release - Before Market Open (NASDAQ:ALKS) - February 16 at 8:33 PM logoQ4 2016 Alkermes Plc Earnings Release - Before Market Open (NASDAQ:ALKS) - February 16 at 8:33 PM logoALKERMES PLC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits (NASDAQ:ALKS) - February 16 at 8:33 PM logoALKERMES PLC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits (NASDAQ:ALKS) - February 16 at 8:33 PM logoALKERMES PLC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits (NASDAQ:ALKS) - February 16 at 8:33 PM logoAlkermes reports 4Q loss (NASDAQ:ALKS) - February 16 at 8:33 PM logoAlkermes reports 4Q loss (NASDAQ:ALKS) - February 16 at 8:33 PM logoAlkermes reports 4Q loss (NASDAQ:ALKS) - February 16 at 8:33 PM logoAlkermes (ALKS) Q4 Loss Narrower than Expectations, Sales Beat (NASDAQ:ALKS) - February 16 at 8:33 PM logoAlkermes (ALKS) Q4 Loss Narrower than Expectations, Sales Beat (NASDAQ:ALKS) - February 16 at 8:33 PM logoAnalyst Activity – Cantor Fitzgerald Reiterates Neutral on Alkermes PLC (NASDAQ:ALKS) - Market Exclusive (NASDAQ:ALKS) - February 16 at 3:32 PM logoAlkermes' Revenue Soars, Projects an Exciting Year Ahead (NASDAQ:ALKS) - February 16 at 3:31 PM logoAlkermes Plc :ALKS-US: Earnings Analysis: Q4, 2016 By the Numbers : February 16, 2017 (NASDAQ:ALKS) - February 16 at 3:31 PM
News IconTechnical Updates for Alkermes plc (ALKS) - Midway Monitor (NASDAQ:ALKS) - February 16 at 8:07 AM logoAlkermes plc (ALKS): Looking to 2018 - Cantor Fitzgerald - (NASDAQ:ALKS) - February 16 at 8:07 AM logoAlkermes Plc (ALKS) Q4 2016 Results - Earnings Call Transcript - Seeking Alpha (NASDAQ:ALKS) - February 16 at 8:07 AM logoEdited Transcript of ALKS earnings conference call or presentation 15-Feb-17 1:30pm GMT (NASDAQ:ALKS) - February 16 at 8:07 AM logoAlkermes Plc Earnings Call (Q4 2016) (NASDAQ:ALKS) - February 14 at 9:04 PM logoAlkermes : to Host Conference Call to Discuss Fourth Quarter and Year-End 2016 Financial Results (NASDAQ:ALKS) - February 13 at 8:58 PM logoWhy Sage Therapeutics Jumped Today (NASDAQ:ALKS) - February 13 at 8:58 PM
News IconShares Observed in Overbought Territory: Alkermes plc (NASDAQ:ALKS) - Aiken Advocate (NASDAQ:ALKS) - February 13 at 3:55 PM
News IconTrading Review: Technical Survey on Shares of Alkermes plc (ALKS) - Davidson Register (NASDAQ:ALKS) - February 7 at 8:57 PM logoIs Alkermes Poised for a Comeback in 2017? (NASDAQ:ALKS) - February 6 at 3:29 PM logoNaltrexone Showing More Potential in Drug Addiction Treatment Market (NASDAQ:ALKS) - February 5 at 8:28 PM logoAlkermes to expand manufacturing capacity, add new jobs (NASDAQ:ALKS) - February 3 at 3:36 PM
News IconEarnings Parade Rolls On, What Are Analysts Saying About Alkermes plc (NASDAQ:ALKS)? - Wall Street Beacon (NASDAQ:ALKS) - January 31 at 3:36 PM
News IconInvestor Sphere: Keeping an Eye on Levels for Alkermes plc (ALKS) - Springdale Times (NASDAQ:ALKS) - January 29 at 3:24 PM
News IconCheck on Average Directional Index for Alkermes plc (ALKS) - Market Point (NASDAQ:ALKS) - January 28 at 8:30 PM
News IconInvestor Chatter: Tracking Technical Indicators for Alkermes plc (ALKS) - Market Point (NASDAQ:ALKS) - January 26 at 1:35 AM logoMeet Morningstar's 2016 top domestic fund manager (NASDAQ:ALKS) - January 25 at 3:32 PM
News IconEarnings in Full Force, Analysts Take Aim at Alkermes plc (NASDAQ:ALKS) - Wall Street Beacon (NASDAQ:ALKS) - January 24 at 3:49 PM logoBioCorRx Receives New Funding for Opioid Drug (NASDAQ:ALKS) - January 22 at 3:24 PM
News IconStock Update on Earnings & Estimates for Alkermes plc (NASDAQ:ALKS) - Aiken Advocate (NASDAQ:ALKS) - January 20 at 3:59 PM
News IconEVP, R&D & CMO, Alkermes, Inc. of Alkermes plc – Ordinary Shares (NASDAQ:ALKS), Ehrich Elliot, sells 11,983 shares worth $650,945 (NASDAQ:ALKS) - January 18 at 9:01 PM
News IconFocus Equity: Stock Strength Indicator Update on Alkermes plc (NASDAQ:ALKS) - Wall Street Beacon (NASDAQ:ALKS) - January 17 at 10:09 AM
News IconWill The Needle Move For Alkermes plc (NASDAQ:ALKS) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:ALKS) - January 17 at 10:09 AM logoLifePoint Health : Healthcare Stocks Under Scanner -- Valeant Pharma, Alkermes, Universal Health Services, and LifePoint Health (NASDAQ:ALKS) - January 13 at 3:51 PM logoMott Capital Says Netflix (NFLX) At Forefront of Paradigm Shift, Talks Disney, Hain, NXPI Deal, More (NASDAQ:ALKS) - January 13 at 3:51 PM logoAlkermes plc (NASDAQ:ALKS) Records An Impact Score Of 54 - Investor Newswire (NASDAQ:ALKS) - January 12 at 8:34 PM
News IconStock Getting Tripped Up In Session: Alkermes plc (NASDAQ:ALKS) - Wall Street Beacon (NASDAQ:ALKS) - January 11 at 3:45 PM
News IconStock Reaching Most Volatile List Today: Alkermes plc (NASDAQ:ALKS) - Wall Street Beacon (NASDAQ:ALKS) - January 11 at 3:45 PM logoInsider Trading Activity Alkermes PLC (NASDAQ:ALKS) – Director Sold 4000 shares of Stock - Market Exclusive (NASDAQ:ALKS) - January 9 at 3:39 PM
News IconAlkermes Plc (NASDAQ:ALKS) Heffx Trading Outlook - Live Trading News (NASDAQ:ALKS) - January 9 at 3:39 PM


What is Alkermes PLC's stock symbol?

Alkermes PLC trades on the NASDAQ under the ticker symbol "ALKS."

Where is Alkermes PLC's stock going? Where will Alkermes PLC's stock price be in 2017?

10 brokerages have issued 1 year price targets for Alkermes PLC's shares. Their predictions range from $35.00 to $78.00. On average, they expect Alkermes PLC's stock price to reach $61.27 in the next twelve months.

When will Alkermes PLC announce their earnings?

Alkermes PLC is scheduled to release their next quarterly earnings announcement on Thursday, February, 23rd 2017.

What are analysts saying about Alkermes PLC stock?

Here are some recent quotes from research analysts about Alkermes PLC stock:

  • According to Zacks Investment Research, "Alkermes boasts a diversified portfolio of products targeting major CNS disorders including schizophrenia, depression, addiction and multiple sclerosis. Revenues are driven not only by the company’s royalty and manufacturing business, but also by a strong performance of Vivitrol and Aristada. Alkermes sees both Vivitrol and Aristada as growth drivers. While Vivitrol should benefit from the newly passed legislation, CARA, securing reimbursement and access for Aristada also bodes well. Meanwhile, Alkermes’ progress with its pipeline has been impressive. Focus should be on the same as the company expects important data readouts over the next several quarters. Given its history of pipeline setbacks, any obstacle in the process of development of these candidates would weigh heavily on the stock. Stiff competition and dependence on partners remains a threat. Shares of the company have underperformed the broader industry year to date." (12/13/2016)

  • J P Morgan Chase & Co analysts commented, "Importantly 5461 continued to be well tolerated, in line with prior studies. ALKS plans to meet with the FDA in early 1Q17 to discuss filing, and we continue to think positive FORWARD-5 data makes the totality of the data approvable [...] Further confirmation of an NDA filing based on data in hand, as well as, clarity on the filing timeline will be key in 2017." (10/21/2016)

  • Morgan Stanley analysts commented, "We are raising our PT from $18 (11x old F17e of 1.64) to $23 (16x new F17e of $1.42) since downside from US MFA (antibiotic medicated feed additive) pressures appears limited." (9/2/2016)

Who owns Alkermes PLC stock?

Alkermes PLC's stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (15.00%), State Street Corp (2.46%), Franklin Resources Inc. (1.83%), Frontier Capital Management Co. LLC (0.62%), Federated Investors Inc. PA (0.53%) and Marshall Wace LLP (0.42%). Company insiders that own Alkermes PLC stock include David Joseph Gaffin, David W Anstice, Elliot Ehrich, Gordon G Pugh, Iain Michael Brown, James M Frates, Kathryn L Biberstein, Mark Stejbach, Michael J Landine, Paul J Mitchell, Rebecca Peterson, Richard F Pops, Robert A Breyer and Shane Cooke.

Who sold Alkermes PLC stock? Who is selling Alkermes PLC stock?

Alkermes PLC's stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Janus Capital Management LLC, Asset Management One Co. Ltd., Castleark Management LLC, Guggenheim Capital LLC, Frontier Capital Management Co. LLC, Raymond James Financial Services Advisors Inc. and Teachers Retirement System of The State of Kentucky. Company insiders that have sold Alkermes PLC stock in the last year include David Joseph Gaffin, Elliot Ehrich, Gordon G Pugh, Iain Michael Brown, James M Frates, Kathryn L Biberstein, Mark Stejbach, Michael J Landine, Paul J Mitchell, Richard F Pops, Robert A Breyer and Shane Cooke.

Who bought Alkermes PLC stock? Who is buying Alkermes PLC stock?

Alkermes PLC's stock was acquired by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Credit Agricole S A, A.R.T. Advisors LLC, Allianz Asset Management AG, State Street Corp, FMR LLC, Two Sigma Investments LP and Turner Investments LLC.

How do I buy Alkermes PLC stock?

Shares of Alkermes PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Alkermes PLC stock cost?

One share of Alkermes PLC stock can currently be purchased for approximately $54.57.

Alkermes PLC (NASDAQ:ALKS) Chart for Tuesday, February, 21, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Alkermes PLC (NASDAQ:ALKS)

Earnings History Chart

Earnings by Quarter for Alkermes PLC (NASDAQ:ALKS)

Dividend History Chart

Dividend Payments by Quarter for Alkermes PLC (NASDAQ:ALKS)

Last Updated on 2/21/2017 by Staff